Latest Global Health News

Global Health Limited reported a reduced net loss for FY2025, driven by growing subscription revenue and strategic AI integration as it transitions to a SaaS platform.

AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.

Orora Limited reported solid FY25 financial results driven by strong performance in its Cans business and the Saverglass acquisition, alongside key capacity expansions and glass network optimizations. The company’s robust balance sheet supports ongoing shareholder returns and a positive outlook for FY26.

Global Health Limited has secured a $186,748 contract to implement its MasterCare+ digital platform at Jarrah House, enhancing alcohol and other drug (AOD) services with tailored technology solutions.

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.

Global Health Limited reported a robust June quarter with a 65% rise in annual sales and a strategic pivot towards AI-driven efficiencies, aiming for profitability by mid-2026.

AdAlta Limited has prioritized two promising CAR-T cellular immunotherapy products for licensing agreements and successfully raised $1.3 million to support its strategic expansion. The company’s focused capital management and pipeline refinement signal a pivotal phase in its ‘East to West’ strategy.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.

Biotron Limited has completed the initial safety phase of its lead Hepatitis B drug in animal studies, paving the way for efficacy testing in two distinct mouse models. This milestone marks a significant step forward in the company’s antiviral drug development program.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

Island Pharmaceuticals has reported encouraging Phase 2a/b trial results for ISLA-101, demonstrating meaningful reductions in dengue viral load and symptoms in humans. The findings support further clinical development of this antiviral candidate.